Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 10 to 16

Using Dysport® with bracing to treat adolescent idiopathic scoliosis

Official title: Dysport ® (abobotulinumtoxinA) as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis

Run by Johns Hopkins University · NCT03935295 · Data updated 2026-11-12

This study is testing if using Dysport® injections along with a brace can help kids aged 10-16 with scoliosis have better results and prevent their spine from getting worse.

More Adolescent Idiopathic Scoliosis trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages10 Years to 16 Years
SexAll
Enrollment90 (estimated)
SponsorJohns Hopkins University
Academic / other
Locations1 site (Baltimore, Maryland)
StatusRecruiting
StartedSeptember 3, 2020
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedDecember 9, 2025
Trial IDNCT03935295 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are skeletally immature children aged 10-16 years with idiopathic scoliosis, a major curve of 20°-40°, and who can adhere to a bracing protocol.

Probably not a fit

Patients with congenital or neuromuscular scoliosis, previous spinal surgery, or those currently requiring surgery will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of botulinum toxin A (Dysport®) as an adjunctive treatment alongside bracing for children with adolescent idiopathic scoliosis (AIS). It involves administering Dysport® injections into the paraspinal muscles of the concave side of the major curve in skeletally immature patients aged 10-16 years. The study compares outcomes between patients receiving Dysport® and those receiving a placebo, both while adhering to a bracing protocol. The goal is to determine if Dysport® can reduce curve progression and improve the effectiveness of bracing in managing AIS.

Why it matters

Potential benefit: If successful, this approach could establish a new standard of nonoperative care for adolescent idiopathic scoliosis, potentially reducing the need for surgical interventions.

How similar studies have gone: While there is limited research on the use of botulinum toxin as an adjunct therapy in scoliosis treatment, this approach is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

* Clinically determined idiopathic nature of scoliosis
* Age 10-16 years
* Risser stage 0,1,or 2
* major curve of 20°-40°
* curve apex caudal to T7 vertebra
* ability to adhere to bracing protocol
* Botulinum toxin naïve or previously treated greater than 6 months prior to study entry

Exclusion criteria:

* Diagnosis of congenital scoliosis, neuromuscular scoliosis, or other "reason" for scoliosis - Previous surgery at any segment of the spine
* Current need for surgery at any level of the spine
* Treatment with any drug known to interfere with neuromuscular function
* Any other medical condition, laboratory or diagnostic procedure finding that might preclude administration of BTX
* Ongoing infection at the injection sites
* Diagnosis as either resistant or sensitive to botulinum toxin treatment of any type or to any components of the BTX formulation
* Cow milk protein allergy

Where it's running

  • Johns Hopkins University
    Baltimore, Maryland, United States
    Recruiting

Study contacts

  • Principal investigator: Paul Sponseller, MD, MBA — Johns Hopkins Hospital Department of Orthopaedic Surgery
  • Study coordinator: Gabrielle Reichard, MA
  • Email: greicha1@jhmi.edu
  • Phone: 4105023626

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.